Blood filters in children with COVID-19 and acute kidney injury: A review.
COVID-19
CVVHDF
CytoSorb
blood filters
oXiris
Journal
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
ISSN: 1744-9987
Titre abrégé: Ther Apher Dial
Pays: Australia
ID NLM: 101181252
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
revised:
11
12
2021
received:
25
09
2021
accepted:
03
01
2022
pubmed:
9
1
2022
medline:
3
5
2022
entrez:
8
1
2022
Statut:
ppublish
Résumé
COVID-19 has challenged the global healthcare system through rapid proliferation and lack of existing treatment resulting in over 180 million cases and 3.8 million deaths since December 2019. Although pediatric patients only comprise 1%-2% of diagnosed cases, their incidence of acute kidney injury ranges from 8.2% to 18.2% compared to 49% in adults. Severe infection, initiated by dysregulated host response, can lead to multiorgan failure. In this review, we focus on the use of various blood filters approved for use in pediatric kidney replacement therapy to mitigate adverse effects of severe illness. Therapeutic effects of these blood filters range from cytokine removal (CytoSorb, HA330, HCO/MCO), endotoxin removal (Toraymyxin, CPFA), both cytokine and endotoxin removal (oXiris), and nonspecific removal of proteins (PMMA) that have already been established and can be used to mitigate the various effects of the cytokine storm syndrome in COVID-19.
Identifiants
pubmed: 34997670
doi: 10.1111/1744-9987.13793
doi:
Substances chimiques
Cytokines
0
Endotoxins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
566-582Informations de copyright
© 2022 International Society for Apheresis and Japanese Society for Apheresis.
Références
Esakandari H, Nabi-Afjadi M, Fakkari-Afjadi J, Farahmandian N, Miresmaeili SM, Bahreini E. A comprehensive review of COVID-19 characteristics. Biol Proced Online. 2020;22:19. https://doi.org/10.1186/s12575-020-00128-2
WHO coronavirus disease (COVID-19) dashboard. Geneva: World Health Organization, 2020. [cited 2021 Apr 17]. Available from: https://covid19.who.int/.
Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2020;93:250-6. https://doi.org/10.1002/jmv.26232
Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr. 2020;87(4):281-6. https://doi.org/10.1007/s12098-020-03263-6
Rabinowicz S, Leshem E, Pessach IM. COVID-19 in the pediatric population-review and current evidence. Curr Infect Dis Rep. 2020;22(11):29. https://doi.org/10.1007/s11908-020-00739-6
Tripathi S, Gist KM, Bjornstad EC, Kashyap R, Boman K, Chiotos K, et al. Coronavirus disease 2019-associated PICU admissions: a report from the Society of Critical Care Medicine discovery network viral infection and respiratory illness universal study registry. Pediatr Crit Care Med. 2021;22(7):603-15. https://doi.org/10.1097/PCC.0000000000002760
Basalely A, Gurusinghe S, Schneider J, Shah SS, Siegel LB, Pollack G, et al. Acute kidney injury in pediatric patients hospitalized with acute COVID-19 and multisystem inflammatory syndrome in children associated with COVID-19. Kidney Int. 2021;100:138-45. https://doi.org/10.1016/j.kint.2021.02.026
Wang F, Ran L, Qian C, Hua J, Luo Z, Ding M, et al. Epidemiology and outcomes of acute kidney injury in COVID-19 patients with acute respiratory distress syndrome: a multicenter retrospective study. Blood Purif. 2020;50:499-505. https://doi.org/10.1159/000512371
García LF. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol. 2020;11:1441. https://doi.org/10.3389/fimmu.2020.01441
Pan XW, Xu D, Zhang H, Zhou W, Wang LH, Cui XG. Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis. Intensive Care Med. 2020;46(6):1114-6. https://doi.org/10.1007/s00134-020-06026-1
Honore PM, Hoste E, Molnár Z, Jacobs R, Joannes-Boyau O, Malbrain MLNG, et al. Cytokine removal in human septic shock: where are we and where are we going? Ann Intensive Care. 2019;9:56. https://doi.org/10.1186/s13613-019-0530-y
Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. https://doi.org/10.1016/j.jaut.2020.102433
Nadim MK, Forni LG, Mehta RL, Connor MJ Jr, Liu KD, Ostermann M, et al. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. Nat Rev Nephrol. 2020;16:747-64. https://doi.org/10.1038/s41581-020-00356-5
Bottari G, Confalone V, Cotugno N, Guzzo I, Perdichizzi S, Manno EC, et al. Efficacy of CytoSorb in a Pediatric Case of Severe Multisystem Infammatory Syndrome (MIS-C): a clinical case report. Front Pediatr. 2021;9:676298. https://doi.org/10.3389/fped.2021.676298
Ronco C, Bagshaw SM, Bellomo R, Clark WR, Husain-Syed F, Kellum JA, et al. Extracorporeal blood purification and organ support in the critically ill patient during COVID-19 pandemic: expert review and recommendation. Blood Purif. 2020;50:17-27. https://doi.org/10.1159/000508125
Ascierto PA, Fu B, Wei H. IL-6 modulation for COVID-19: the right patients at the right time? J Immunother Cancer. 2021;9(4):e002285. https://doi.org/10.1136/jitc-2020-002285
Chi Z, Zhao W, Jia-Wen L, Hong Z, Gui-Qiang W. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab man be the key to reduce the mortality. Int J Antimicrob Agents. 2020;55(5):105954.
Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:E005. https://doi.org/10.3760/cma.j.issn.1001-0939.2020.0005
Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020;53:25-32. https://doi.org/10.1016/j.cytogfr.2020.05.003
Pfortmueller CA, Meisel C, Fux M, Schefold JC. Assessment of immune organ dysfunction in critical illness: utility of innate immune response markers. Intensive Care Med Exp. 2017;5:49.
Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013;13:260-8.
Rosalia RA, Ugurov P, Neziri D, Despotovska S, Kostoska E, Kiridjievska LV, et al. Extracorporeal blood purification in moderate and severe COVID-19 patients: a prospective cohort study. medRxiv. 2020;1-10. https://doi.org/10.1101/2020.10.10.20210096
Malard B, Lambert C, Kellum JA. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices. Intensive Care Med Exp. 2018;6(1):12. https://doi.org/10.1186/s40635-018-0177-2
Bottari G, Guzzo I, Marano M, Stoppa F, Ravà L, Di Nardo M, et al. Hemoperfusion with Cytosorb in pediatric patients with septic shock: a retrospective observational study. Int J Artif Organs. 2020;43(9):587-93. https://doi.org/10.1177/0391398820902469
Raina R, Chakraborty R, Sethi SK, Bunchman T. Kidney replacement therapy in COVID-19 induced kidney failure and septic shock: a Pediatric Continuous Renal Replacement Therapy [PCRRT] position on emergency preparedness with resource allocation. Front Pediatr. 2020;8:413. https://doi.org/10.3389/fped.2020.00413
Tandukar S, Palevsky PM. Continuous renal replacement therapy: who, when, why, and how. Chest. 2019;155(3):626-38. https://doi.org/10.1016/j.chest.2018.09.004
Fu D, Yang B, Xu J, Mao Z, Zhou C, Xue C. COVID-19 infection in a patient with end-stage kidney disease. Nephron. 2020;144(5):245-7. https://doi.org/10.1159/000507261
Nadim MK, Forni LG, Mehta RL, Connor MJ Jr, Liu KD, Ostermann M, et al. Publisher correction: COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. Nat Rev Nephrol. 2020;16(12):765. https://doi.org/10.1038/s41581-020-00372-5
Chen LX, Demirjian S, Udani SM, Trevino SA, Murray PT, Koyner JL. Cytokine clearances in critically ill patients on continuous renal replacement therapy. Blood Purif. 2018;46(4):315-22. https://doi.org/10.1159/000492025
Turani F, Barchetta R, Falco M, Busatti S, Weltert L. Continuous renal replacement therapy with the adsorbing filter oXiris in septic patients: a case series. Blood Purif. 2019;47(Suppl 3):1-5. https://doi.org/10.1159/000499589
Ning B, Ye S, Lyu Y, Yin F, Chen Z. Effect of high-volume hemofiltration on children with sepsis. Transl Pediatr. 2020;9(2):101-7. https://doi.org/10.21037/tp.2020.03.13
Miao H, Wang F, Xiong X, Wang C, Zhang Y. Clinical benefits of high-volume hemofiltration in critically ill pediatric patients with severe sepsis: a retrospective cohort study. Blood Purif. 2018;45(1-3):18-27. https://doi.org/10.1159/000481249
Meng SQ, Yang WB, Liu JG, Yuan JY, Zhang K, Ding WY, et al. Evaluation of the application of high-volume hemofiltration in sepsis combined with acute kidney injury. Eur Rev Med Pharmacol Sci. 2018;22(3):715-20. https://doi.org/10.26355/eurrev_201802_14298
Zhang H, Zhu G, Yan L, Lu Y, Fang Q, Shao F. The absorbing filter Oxiris in severe coronavirus disease 2019 patients: a case series. Artif Organs. 2020;44(12):1296-302. https://doi.org/10.1111/aor.13786
Villa G, Romagnoli S, De Rosa S, Greco M, Resta M, Montin DP, et al. Blood purification therapy with a hemodiafilter featuring enhanced adsorptive properties for cytokine removal in patients presenting COVID-19: a pilot study. Crit Care. 2020;24:605. https://doi.org/10.1186/s13054-020-03322-6
Raina R, Bedoyan JK, Lichter-Konecki U, Jouvet P, Picca S, Mew NA, et al. Consensus guidelines for management of hyperammonaemia in paediatric patients receiving continuous kidney replacement therapy. Nat Rev Nephrol. 2020;16(8):471-82. https://doi.org/10.1038/s41581-020-0267-8
Zhou F, Peng Z, Murugan R, Kellum JA. Blood purification and mortality in sepsis: a meta-analysis of randomized trials. Crit Care Med. 2013;41(9):2209-20. https://doi.org/10.1097/CCM.0b013e31828cf412
Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301(23):2445-52. https://doi.org/10.1001/jama.2009.856
Saparov A, Sazonov V, Tobylbaeva Z, Isakov S, Bekpan A, Autalipov D, et al. First successful hemoadsorption using CytoSorb in a septic pediatric patient in Kazakhstan: a case report. Int J Artif Organs. 2019;42(6):315-7. https://doi.org/10.1177/0391398818819953
Villa G, Zaragoza JJ, Sharma A, Neri M, De Gaudio AR, Ronco C. Cytokine removal with high cut-off membrane: review of literature. Blood Purif. 2014;38(3-4):167-73. https://doi.org/10.1159/000369155
Cirstoveanu CG, Barascu I, Mc Kenzie Stancu S. Hemadsorption with adult CytoSorb in a low weight pediatric case. Case Rep Crit Care. 2017;2017:6987167. https://doi.org/10.1155/2017/6987167
Kellum JA, Venkataraman R, Powner D, Elder M, Hergenroeder G, Carter M. Feasibility study of cytokine removal by hemoadsorption in brain-dead humans. Crit Care Med. 2008;36(1):268-72. https://doi.org/10.1097/01.CCM.0000291646.34815.BB
Nassiri AA, Hakemi MS, Miri MM, Shahrami R, Koomleh AA, Sabaghian T. Blood purification with CytoSorb in critically ill COVID-19 patients: a case series of 26 patients. Artif Organs. 2021;45(11):1338-47. https://doi.org/10.1111/aor.14024
Brescia Renal Covid Task Force; Alberici Felbarba E, Manenti C, Econimo L, Valerio F, et al. Management of patients on dialysis and with kidney transplant during COVID-19 infection. Kidney International reports; 2020 [cited 2021 March 13]. Available from: https: //www.era-edta.org/en/wp-content/uploads/2020/03/COVID_guidelines_finale_eng-GB.pdf.
China National Health Commission. Chinese clinical guidance for COVID-19 pneumonia diagnosis and treatment. 7th ed.; ACC News Story; 2020 Available from: http://kjfy.meetingchina.org/msite/news/show/cn/3337.html
Rampino T, Gregorini M, Perotti L, Ferrari F, Pattonieri EF, Grignano MA, et al. Hemoperfusion with CytoSorb as adjuvant therapy in critically ill patients with SARS-CoV2 pneumonia. Blood Purif. 2020;2020:1-6. https://doi.org/10.1159/000511725
Rizvi S, Danic M, Silver M, LaBond V. Cytosorb filter: an adjunct for survival in the COVID-19 patient in cytokine storm? A case report. Heart Lung. 2021;50(1):44-50. https://doi.org/10.1016/j.hrtlng.2020.09.007
Bottari G, Taccone FS, Moscatelli A. Hybrid blood purification strategy in pediatric septic shock. Crit Care. 2016;20(1):366. https://doi.org/10.1186/s13054-016-1535-7
Berkes A, Szikszay E, Kappelmayer J, Kerényi A, Szabó T, Ujhelyi L, et al. Use of hemadsorption in a case of pediatric toxic shock syndrome. Case Rep Crit Care. 2017;2017:3818407. https://doi.org/10.1155/2017/3818407
Kogelmann K, Jarczak D, Scheller M, Drüner M. Hemoadsorption by CytoSorb in septic patients: a case series. Crit Care. 2017;21(1):74. https://doi.org/10.1186/s13054-017-1662-9
Brouwer WP, Duran S, Kuijper M, Ince C. Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study. Crit Care. 2019;23(1):317. https://doi.org/10.1186/s13054-019-2588-1
Haase M, Bellomo R, Baldwin I, Haase-Fielitz A, Fealy N, Davenport P, et al. Hemodialysis membrane with a high-molecular-weight cutoff and cytokine levels in sepsis complicated by acute renal failure: a phase 1 randomized trial. Am J Kidney Dis. 2007;50(2):296-304. https://doi.org/10.1053/j.ajkd.2007.05.003
Fanelli V, Ranieri VM. Mechanisms and clinical consequences of acute lung injury. Ann Am Thorac Soc. 2015;12(Suppl 1):S3-8. https://doi.org/10.1513/AnnalsATS.201407-340MG
Kaçar CK, Uzundere O, Kandemir D, Yektaş A. Efficacy of HA330 hemoperfusion adsorbent in patients followed in the intensive care unit for septic shock and acute kidney injury and treated with continuous venovenous hemodiafiltration as renal replacement therapy. Blood Purif. 2020;49(4):448-56. https://doi.org/10.1159/000505565
Huang Z, Wang SR, Su W, Liu JY. Removal of humoral mediators and the effect on the survival of septic patients by hemoperfusion with neutral microporous resin column. Ther Apher Dial. 2010;14(6):596-602. https://doi.org/10.1111/j.1744-9987.2010.00825.x
Huang Z, Wang SR, Yang ZL, Liu JY. Effect on extrapulmonary sepsis-induced acute lung injury by hemoperfusion with neutral microporous resin column. Ther Apher Dial. 2013;17(4):454-61.
Griffiths MJD, McAuley DF, Perkins GD, et al. Guidelines on the management of acute respiratory distress syndrome. BMJ Open Respir Res. 2019;6(1):e000420. https://doi.org/10.1136/bmjresp-2019-000420
Medical SS. SeaStar medical announces positive results from pilot clinical study of the selective cytopheretic device (SCD) in pediatric patients with acute kidney injury. Available from: https://www.prnewswire.com/news-releases/seastar-medical-announces-positive-results-from-pilot-clinical-study-of-the-selective-cytopheretic-device-scd-in-pediatric-patients-with-acute-kidney-injury-301159550.html.
Pino CJ, Westover AJ, Johnston KA, Buffington DA, Humes HD. Regenerative medicine and immunomodulatory therapy: insights from the kidney, heart, brain, and lung. Kidney Int Rep. 2018;3(4):771-83. https://doi.org/10.1016/j.ekir.2017.12.012
Yessayan L, Szamosfalvi B, Napolitano L, Singer B, Kurabayashi K, Song Y, et al. Treatment of cytokine storm in COVID-19 patients with immunomodulatory therapy. ASAIO J. 2020;66(10):1079-83. https://doi.org/10.1097/MAT.0000000000001239
Ronco C, Brendolan A, d'Intini V, Ricci Z, Wratten ML, Bellomo R. Coupled plasma filtration adsorption: rationale, technical development and early clinical experience. Blood Purif. 2003;21(6):409-16.
Netti GS, Sangregorio F, Spadaccino F, Staffieri F, Crovace A, Infante B, et al. LPS removal reduces CD80-mediated albuminuria in critically ill patients with Gram-negative sepsis. Am J Physiol Renal Physiol. 2019;316(4):F723-31. https://doi.org/10.1152/ajprenal.00491.2018
Zhou Z, Kuang H, Ma Y, Zhang L. Application of extracorporeal therapies in critically ill COVID-19 patients. J Zhejiang Univ Sci B. 2021;22(9):701-17. https://doi.org/10.1631/jzus.B2100344
Larsen FS, Schmidt LE, Bernsmeier C, Rasmussen A, Isoniemi H, Patel VC, et al. High-volume plasma exchange in patients with acute liver failure: an open randomised controlled trial. J Hepatol. 2016;64(1):69-78. https://doi.org/10.1016/j.jhep.2015.08.018
Luo S, Yang L, Wang C, Liu C, Li D. Management of COVID-19: the Zhejiang experience. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;49(2):227-31. https://doi.org/10.3785/j.issn.1008-9292.2020.03.06
Honore PM, Mugisha A, Kugener L, Redant S, Attou R, Gallerani A, et al. Therapeutic plasma exchange as a routine therapy in septic shock and as an experimental treatment for COVID-19: we are not sure. Crit Care. 2020;24(1):226. https://doi.org/10.1186/s13054-020-02943-1
Patidar GK, Land KJ, Vrielink H, Rahimi-Levene N, Dann EJ, Al-Humaidan H, et al. Understanding the role of therapeutic plasma exchange in COVID-19: preliminary guidance and practices. Vox Sang. 2021;116(7):798-807. https://doi.org/10.1111/vox.13067
Raina R, McCulloch M, Nourse P, Sethi SK, Yap HK. Advances in kidney replacement therapy in infants. Adv Chronic Kidney Dis. 2021;28(1):91-104. https://doi.org/10.1053/j.ackd.2021.05.002
Sethi SK, Bansal SB, Khare A, Dhaliwal M, Raghunathan V, Wadhwani N, et al. Heparin free dialysis in critically sick children using sustained low efficiency dialysis (SLEDD-f): a new hybrid therapy for dialysis in developing world. PLoS One. 2018;13(4):e0195536. https://doi.org/10.1371/journal.pone.0195536
Askenazi D, Ingram D, White S, Cramer M, Borasino S, Coghill C, et al. Smaller circuits for smaller patients: improving renal support therapy with Aquadex™. Pediatr Nephrol. 2016;31(5):853-60. https://doi.org/10.1007/s00467-015-3259-3
Sanderson KR, Harshman LA. Renal replacement therapies for infants and children in the ICU. Curr Opin Pediatr. 2020;32(3):360-6. https://doi.org/10.1097/MOP.0000000000000894
Spectral Medical Inc. Spectral Medical's CMO recognized as a world expert in sepsis; supports world sepsis day and sepsis awareness month. GlobeNewswire News Room. Available from: https://www.globenewswire.com/news-release/2021/09/13/2295723/0/en/Spectral-Medical-s-CMO-Recognized-as-a-World-Expert-in-Sepsis-Supports-World-Sepsis-Day-and-Sepsis-Awareness-Month.html. 2021.
De Rosa S, Cutuli SL, Ferrer R, Antonelli M, Ronco C, COVID-19 EUPHAS2 Collaborative Group. Polymyxin B hemoperfusion in coronavirus disease 2019 patients with endotoxic shock: case series from EUPHAS2 registry. Artif Organs. 2020;45:E187-94. https://doi.org/10.1111/aor.13900
Katagiri D, Ishikane M, Asai Y, Izumi S, Takasaki J, Katsuoka H, et al. Direct hemoperfusion using a polymyxin B-immobilized polystyrene column for COVID-19. J Clin Apher. 2021;36(3):313-21. https://doi.org/10.1002/jca.21861
Dellinger RP, Bagshaw SM, Antonelli M, Foster DM, Klein DJ, Marshall JC, et al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. JAMA. 2018;320(14):1455-63. https://doi.org/10.1001/jama.2018.14618
Ankawi G, Fan W, Pomarè Montin D, Lorenzin A, Neri M, Caprara C, et al. A new series of sorbent devices for multiple clinical purposes: current evidence and future directions. Blood Purif. 2019;47(1-3):94-100. https://doi.org/10.1159/000493523
Livigni S, Bertolini G, Rossi C, et al. Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: a multicenter randomised controlled clinical trial. BMJ Open. 2014;4(1):e003536. https://doi.org/10.1136/bmjopen-2013-003536
Ronco C, Brendolan A, Lonnemann G, Bellomo R, Piccinni P, Digito A, et al. A pilot study of coupled plasma filtration with adsorption in septic shock. Crit Care Med. 2002;30(6):1250-5. https://doi.org/10.1097/00003246-200206000-00015
Nakamura A, Niiyama S, Yamaga O, Takasu O, Yamashita N, Ushijima K, et al. Comparison of two membrane hemofilters (polymethyl methacrylate vs. polyacrylonitrile) for absorption of high concentrations of IL-6 and HMGB1 in human waste plasma. Crit Care Med. 2012;40:1-328. https://doi.org/10.1097/01.ccm.0000424437.95245.ea
Miyamoto T, Yoshimoto A, Tatsu K, Ikeda K, Ishii Y, Kobayashi T. Zero mortality of continuous veno-venous hemodiafiltration with PMMA hemofilter after pediatric cardiac surgery. Ann Thorac Cardiovasc Surg. 2011;17(4):352-5.
Zarbock A, Kellum JA, Schmidt C, van Aken H, Wempe C, Pavenstädt H, et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA. 2016;315(20):2190-9. https://doi.org/10.1001/jama.2016.5828
Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, et al. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med. 2021;181(1):41-51. https://doi.org/10.1001/jamainternmed.2020.6252
Malgie J, Schoones JW, Pijls BG. Decreased mortality in coronavirus disease 2019 patients treated with tocilizumab: a rapid systematic review and meta-analysis of observational studies. Clin Infect Dis. 2020;72(11):20.
Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393.
Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020;92:814-8.
Montesarchio V, Parella R, Iommelli C, Bianco A, Manzillo E, Fraganza F, et al. Outcomes and biomarker analyses among patients with COVID-19 treated with Interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy. J Immunother Cancer. 2020;8:e001089.
Cascella M, Mauro I, De Blasio E, et al. Rapid and impressive response to a combined treatment with single-dose tocilizumab and NIV in a patient with COVID-19 pneumonia/ARDS. Medicina. 2020;56:377.
Perrone F, Piccirillo MC, Ascierto PA, Salvarani C, Parrella R, Marata AM, et al. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. J Transl Med. 2020;18(1):405. https://doi.org/10.1186/s12967-020-02573-9